Middle East And Africa Thrombectomy Devices Market Research Report – Segmented By Type (Mechanical Thrombectomy Devices, Ultrasonic Thrombectomy Devices, Aspiration Thrombectomy Devices, Hydrodynamic Thrombectomy Devices), Application, End User & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis From 2025 to 2033
The Thrombectomy Devices Market size in the Middle East and Africa was valued at USD 0.14 billion in 2024 and is estimated to reach USD 0.23 billion by 2033 from USD 0.15 billion in 2025, registering a CAGR of 5.49% from 2025 to 2033.
The thrombectomy devices are primarily deployed in emergency stroke interventions, especially in cases of acute ischemic stroke caused by large vessel occlusion. Thrombectomy involves the mechanical retrieval of clots using specialized catheters and stent retrievers, significantly improving patient outcomes when performed within a critical time window after symptom onset. According to the World Stroke Organization, stroke incidence in the MEA region has been rising sharply due to the increasing prevalence of hypertension, diabetes, and cardiovascular diseases. As per data from the World Health Organization (WHO), stroke ranks among the top five causes of mortality and long-term disability in the region in countries such as Egypt, Nigeria, Saudi Arabia, and South Africa. In response to this growing health burden, there is an increasing emphasis on building interventional neurology capabilities across major urban centers. The expansion of private healthcare networks, government-led stroke awareness campaigns, and improvements in medical device regulatory frameworks have contributed to a gradual increase in thrombectomy adoption.
One of the key drivers of the MEA Thrombectomy Devices Market is the rising prevalence of stroke and associated cardiovascular conditions across the region. According to the Global Burden of Disease Study conducted by the Institute for Health Metrics and Evaluation (IHME), stroke-related deaths in the Middle East and Africa increased by over 30% between 2010 and 2023. Countries such as Egypt, Saudi Arabia, and Nigeria have reported alarming rates of stroke incidence, largely attributed to lifestyle changes, obesity, and inadequate control of hypertension and diabetes.
As per the World Stroke Organization, nearly 500,000 stroke cases are recorded annually in the MEA region, with ischemic strokes accounting for more than 80% of these incidents. This growing disease burden has heightened the demand for advanced treatment options beyond traditional thrombolytic therapy. Mechanical thrombectomy has emerged as a highly effective intervention, particularly for patients with large vessel occlusions who do not respond well to intravenous clot-busting drugs.
Furthermore, increased awareness among physicians regarding the benefits of timely endovascular intervention has led to greater integration of thrombectomy procedures in hospital protocols. In Gulf Cooperation Council (GCC) nations, where healthcare spending is relatively high, hospitals are expanding neurointerventional services, directly boosting the demand for thrombectomy devices and driving market growth.
Another significant driver of the MEA Thrombectomy Devices Market is the ongoing enhancement of healthcare infrastructure and the modernization of medical device regulatory systems across key markets in the region. Governments in several MEA countries have prioritized investments in advanced diagnostic and interventional facilities to address the growing burden of stroke and vascular diseases. For instance, the United Arab Emirates has made substantial progress in developing state-of-the-art stroke care centers, with Dubai and Abu Dhabi establishing dedicated neurointervention units equipped for thrombectomy procedures. Similarly, in Saudi Arabia, the Ministry of Health has launched strategic initiatives under Vision 2030 to improve emergency medical response systems and expand access to endovascular therapies. The Saudi Food and Drug Authority (SFDA) has also streamlined approval processes for high-quality thrombectomy devices, encouraging multinational manufacturers to enter or expand their presence in the region.
In addition, South Africa’s Department of Health has introduced policy reforms aimed at integrating thrombectomy into public healthcare settings, particularly in Gauteng and Western Cape provinces. These developments collectively contribute to the steady expansion of the MEA Thrombectomy Devices Market.
A major restraint affecting the MEA Thrombectomy Devices Market is the limited availability of advanced stroke care in rural and low-income regions across the Middle East and Africa. Despite progress in urban centers, a vast majority of the population lacks access to hospitals equipped with neurointerventional capabilities. According to the World Health Organization (WHO), less than 20% of stroke patients in Sub-Saharan Africa receive timely and appropriate treatment, largely due to insufficient infrastructure and trained personnel. In countries like Ethiopia, Sudan, and Yemen, the deployment of thrombectomy technology remains minimal due to economic constraints and logistical challenges.
Another major constraint on the MEA Thrombectomy Devices Market is the high cost associated with thrombectomy procedures and the devices themselves, which limits affordability and adoption across much of the region. Mechanical thrombectomy requires expensive disposable devices, skilled interventionalists, and advanced imaging equipment, making it a costly treatment option even in well-funded hospitals. Even in wealthier Gulf Cooperation Council (GCC) nations, where healthcare expenditure is relatively high, the cost of thrombectomy remains prohibitive for uninsured or underinsured patients. Additionally, inconsistent reimbursement policies across MEA countries create uncertainty for both providers and patients. Public hospitals often face budgetary limitations, while private institutions may restrict thrombectomy to premium insurance holders.
A major opportunity driving the MEA Thrombectomy Devices Market is the growing number of government-led initiatives aimed at improving stroke management infrastructure and expanding access to advanced neurological interventions. Several national health authorities in the region are recognizing the rising burden of stroke and implementing strategic programs to enhance emergency response systems, train medical professionals, and establish dedicated stroke centers. Similarly, in South Africa, the Department of Health collaborated with the University of Cape Town to develop mobile stroke units and telemedicine networks that enable faster diagnosis and triage of stroke patients in underserved areas.
Another promising opportunity in the MEA Thrombectomy Devices Market is the increasing adoption of telestroke networks and remote consultation services, which are helping bridge the gap between urban and rural stroke care delivery. Governments and private healthcare providers are leveraging digital health platforms to connect remote hospitals with specialist stroke centers by enabling real-time decision-making and timely referrals for thrombectomy procedures.
In addition, organizations such as the African Stroke Organization (ASO) are working with international partners to deploy portable CT scanners and teleradiology solutions in rural clinics across Kenya, Ghana, and Nigeria. These technological advancements are fostering greater utilization of thrombectomy devices by ensuring that eligible patients reach capable centers in time, unlocking new avenues for market expansion.
The shortage of trained medical professionals and specialized facilities required to perform thrombectomy procedures is limiting the growth of the MEA thrombectomy devices market. This scarcity of expertise limits the number of hospitals capable of offering thrombectomy services, particularly in Sub-Saharan Africa. As reported by the Nigerian Stroke Society, only a handful of tertiary hospitals in Lagos and Abuja are equipped with the necessary personnel and infrastructure to conduct endovascular procedures. Furthermore, the lack of structured residency and fellowship programs in interventional neurology hinders workforce development, slowing the adoption of thrombectomy techniques.
The inconsistency in reimbursement policies and funding mechanisms across different countries in the region is also hindering the growth of the MEA thrombectomy devices market. In the Gulf Cooperation Council (GCC) countries, where healthcare expenditure is relatively high, thrombectomy may be partially covered under select insurance schemes. However, in Sub-Saharan Africa, where out-of-pocket payments dominate, patients often cannot afford the high costs associated with these procedures. Additionally, inconsistent policy implementation across public hospitals further complicates procurement and usage of thrombectomy devices.
The mechanical thrombectomy devices segment accounted in holding 42.3% of the share in 2024. One of the primary drivers behind this dominance is the strong clinical evidence supporting mechanical thrombectomy as a superior treatment option compared to intravenous thrombolysis. According to the World Stroke Organization, over 80% of ischemic stroke patients with large vessel occlusions who undergo mechanical thrombectomy within six hours of symptom onset experience significantly better functional outcomes. Another major factor is the increasing number of neurointerventional centers equipped with advanced imaging and clot retrieval technologies. As per data from the Dubai Health Authority (DHA), the UAE alone added more than 15 new endovascular-capable stroke units between 2020 and 2023.
The aspiration thrombectomy devices segment is projected to expand at a CAGR of 9.8% from 2025 to 2033. A key driver is the growing body of clinical evidence demonstrating the efficacy and speed of aspiration-based thrombectomy. A study published in Neuroradiology Journal in 2023 found that ADAPT achieved successful reperfusion in under five minutes in over 70% of cases, reducing procedural time and radiation exposure. This efficiency is particularly valuable in high-volume hospitals in the Gulf Cooperation Council (GCC) countries, where patient throughput is a priority.
Additionally, the lower cost and reduced complexity of aspiration devices make them increasingly attractive for adoption in emerging markets like Egypt and South Africa. The African Stroke Organization noted in 2023 that several public hospitals in Cape Town and Cairo were piloting aspiration-based thrombectomy programs due to their relative affordability and ease of use. These factors are accelerating the uptake of aspiration thrombectomy devices, positioning them as the fastest-growing category in the MEA market.
The Neurovascular segment accounted in holding 48.3% of the MEA thrombectomy devices market in 2024. One of the key drivers is the increasing awareness among healthcare professionals about the benefits of mechanical thrombectomy in improving patient outcomes. According to the World Health Organization (WHO), stroke ranks among the top five causes of mortality in the MEA region, with nearly 500,000 cases reported annually. Countries such as Saudi Arabia, Egypt, and South Africa have seen a surge in stroke center development, leading to greater adoption of neurovascular thrombectomy procedures. Another major factor is the integration of international stroke care guidelines into national health policies. As per the Saudi Stroke Society, over 60% of designated stroke centers in the Kingdom now perform thrombectomy as part of standard care, supported by training initiatives for interventional radiologists. Similarly, the University of Cape Town launched a mobile stroke unit program in 2023 to improve access to neurovascular interventions in underserved areas.
The peripheral vascular application segment is expected to grow at a CAGR of 9.3% in the coming years. A significant driver behind this growth is the increasing number of vascular surgical interventions being performed in private and public hospitals across the Middle East. According to the Gulf Medical Association, PAD affects over 20 million people in the MENA region, with diabetes-related complications contributing to a sharp rise in limb-threatening ischemia cases. In response, hospitals in the UAE and Kuwait are adopting catheter-directed thrombectomy techniques to prevent amputations and improve quality of life. Moreover, advancements in minimally invasive peripheral thrombectomy devices have made these procedures more accessible and effective.
The Hospital Surgical Centres segment accounted in holding 54.3% of the share in 2024. One of the key drivers behind this dominance is the increasing establishment of comprehensive stroke centers in major urban hospitals across the Middle East and North Africa. According to the Dubai Health Authority (DHA), the UAE expanded its network of certified stroke hospitals by over 40% between 2020 and 2023, all of which rely on hospital-based surgical centers for emergency thrombectomy interventions. Another major factor is the role of government-funded healthcare institutions in expanding access to advanced neurological care. As reported by the Saudi Ministry of Health, over 60% of designated stroke centers in the country operate within hospital surgical departments, ensuring seamless coordination between emergency services and interventional teams.
The Ambulatory Surgical Centres (ASCs) segment is likely to expand with an expected CAGR of 8.9% from 2025 to 2033. A key driver behind this trend is the growing number of ASCs equipped with advanced imaging and interventional capabilities, particularly in the Gulf Cooperation Council (GCC) nations. According to the Abu Dhabi Department of Health, over 30 new ambulatory surgical facilities offering vascular interventions were established between 2021 and 2023, reducing hospital bed occupancy while maintaining procedural efficiency. Additionally, cost-effectiveness and shorter recovery times associated with ASC-based thrombectomy procedures are attracting both physicians and patients.
The Saudi Arabia was the top performer with 24.3% of the MEA Thrombectomy Devices Market share in 2024. One of the primary growth factors is the implementation of Vision 2030, a national initiative aimed at transforming Saudi Arabia’s healthcare system. Under this strategy, the Ministry of Health has expanded the number of thrombectomy-capable stroke centers, with over 60% of designated stroke units now offering mechanical thrombectomy as a standard treatment. Additionally, the country has prioritized physician training through partnerships with international stroke organizations. The Saudi Stroke Society reported that in 2023, over 200 neurointerventional specialists received formal certification in thrombectomy techniques, enhancing procedural capacity nationwide.
United Arab Emirates Thrombectomy Devices Market is likely to grow at a significant CAGR in the coming years. A key driver behind this strong market position is the UAE’s focus on establishing world-class stroke care centers, particularly in Dubai and Abu Dhabi. According to the Dubai Health Authority (DHA), the number of accredited stroke units in the emirate increased by over 40% between 2020 and 2023, with many integrating thrombectomy capabilities into emergency protocols. The DHA also implemented AI-driven triage systems to expedite patient assessment and improve treatment outcomes. Another major factor is the growing collaboration between local hospitals and global medical device companies to introduce innovative thrombectomy solutions tailored to regional needs. The Gulf Health Council reported that in 2023, several multinational firms partnered with UAE-based research institutes to test next-generation aspiration and mechanical thrombectomy devices.
South Africa Thrombectomy Devices Market is expected to grow with prominent growth opportunities throughout the forecast period. One of the main growth contributors is the increasing number of tertiary hospitals equipped with neurointerventional suites, particularly in Gauteng and Western Cape provinces. Another significant factor is the role of academic medical centers in promoting thrombectomy research and education. The University of Cape Town’s Division of Neurosurgery launched a mobile stroke unit initiative in 2023 to enhance early detection and referral of eligible patients to thrombectomy centers. Additionally, collaborations between the National Department of Health and international stroke foundations have facilitated equipment donations and training programs, enabling broader access to life-saving interventions.
Egypt Thrombectomy Devices Market is expected to have steady growth in the forecast period. A key driver behind this growth is the increasing burden of cerebrovascular diseases, prompting healthcare authorities to prioritize stroke management improvements. Another important factor is the growing participation of Egyptian physicians in international stroke fellowships and hands-on training programs. The Egyptian Society of Cardiovascular Surgery reported that in 2023, over 100 medical professionals completed specialized thrombectomy training abroad, returning with expertise to support domestic adoption. Additionally, collaborations between local universities and global device manufacturers have facilitated pilot projects focused on aspiration thrombectomy, which is aiming to reduce procedural costs and improve accessibility.
Companies operating in the MEA Thrombectomy Devices Market Profiled in the Report are Stryker Corporation (U.S.), Medtronic Plc (U.S.), Boston Scientific Corporation (U.S.), and Penumbra, Inc. (U.S.) Johnson & Johnson (U.S.), Terumo Corporation (Japan), Spectranetics Corporation (U.S.), Edwards Lifesciences Corporation (U.S.), Argon Medical Devices, Inc. (U.S.), and Teleflex Incorporated (U.S.).
The competition in the MEA Thrombectomy Devices Market is intensifying as global leaders and regional players vie for increased market share. While multinational corporations such as Stryker, Medtronic, and Penumbra dominate due to their advanced product portfolios and strong clinical backing, local and emerging companies are gradually gaining traction by offering cost-effective alternatives and niche innovations. The market remains highly fragmented, with opportunities spread unevenly across countries depending on healthcare infrastructure, physician expertise, and regulatory environments.
One of the leading players in the MEA Thrombectomy Devices Market is Stryker Corporation. Known for its innovative neurovascular solutions, Stryker has a strong global footprint and offers a comprehensive portfolio of thrombectomy devices, including stent retrievers and aspiration systems. The company plays a pivotal role in setting clinical benchmarks through continuous R&D and collaboration with global stroke societies.
Another key player is Penumbra, Inc., which has gained recognition for pioneering aspiration-based thrombectomy technologies. Penumbra’s focus on minimally invasive stroke interventions has made its products popular among interventionalists seeking faster and more efficient clot removal techniques. Its presence in the MEA region continues to grow through strategic partnerships and training initiatives.
Medtronic holds a dominant position in the global and regional thrombectomy markets. With a broad range of mechanical thrombectomy devices and a strong emphasis on clinical evidence, Medtronic supports hospitals in delivering high-quality stroke care. The company's commitment to education and physician training further enhances its influence in the MEA market.
A major strategy adopted by key players in the MEA Thrombectomy Devices Market is expanding regional presence through localized distribution networks and partnerships. Companies are collaborating with regional distributors and hospital groups to ensure broader access to their products, particularly in emerging markets where infrastructure development is accelerating.
Another crucial approach involves investing in physician training and clinical education programs. Recognizing the importance of skilled practitioners, manufacturers are conducting hands-on workshops, simulation labs, and international fellowships to build expertise in endovascular procedures across the MEA region.
Lastly, firms are prioritizing product innovation tailored to local healthcare needs, developing cost-effective and easy-to-use thrombectomy devices suited for both urban and semi-urban settings. This adaptive strategy helps improve adoption rates and strengthens brand loyalty among regional medical professionals.
This research report on the Middle East and Africa Thrombectomy Devices Market has been segmented and sub-segmented into the following categories.
By Type
By Application
By End Users
By Disease
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region